In the current Drug News from IMS LifeCycle R&D Focus for the week ending 18th January 2008:
- IONSYS is launched by Janssen Cilag in the UK, Germany and Ireland for the management of acute moderate-to-severe post-operative pain
- Elan and Biogen Idec receive US FDA approval for TYSABRI as a therapy for moderate-to-severe Crohn's disease
- BioAlliance Pharma's LORAMYC is granted marketing authorization in the UK and Denmark for the treatment of oropharyngeal candidiasis
- An MAA filing is submitted by Pharmion for EU approval of VIDAZA for the treatment of patients with higher-risk MDS
- The US FDA approves 2.5 and 5 mg formulations of Lilly's CIALIS as a therapy for erectile dysfunction
- News from the Vaccine Congress 2007
- Movetis is featured in Company Focus
Drug News also has information on product phase changes, clinical trials, Orphan Drug and Fast Track status, and regulatory approval progress.
The licensing section contains 19 stories covering licensing agreements and modifications, including agreements between Biogen Idec, Ophthotech & PDL BioPharma, Eucalyptus & Yissum, Amgen & Anthera, Genentech & Nerviano Medical Sciences, Mochida & Wyeth, Celtic Pharma & Inspiration, Compugen & Merck & Co, and aRigen & Axentis.
Drug News is produced weekly by the IMS LifeCycle R&D Focus editorial team and is available to subscribers in pdf format. Email or telephone +44 (0) 207 393 5757 for subscription details also you can view our current offerings.